PLK1 and cancer: In subsequent pharmaceutical efforts, new PLK1 inhibitors such as GSK461364A [11], and PHA-680626 [12] were all developed to inhibit PLK1 with low nanomolar IC50s and exert potent antiproliferative effects on various cancer cells.